Innovation Pharmaceuticals develops small molecule therapies to treat cancer, antibiotics, and inflammatory disease. The company focuses on the development of compounds, including Kevetrin, an anti-cancer compound that has completed Phase I clinical trial; and Prurisol, an anti-psoriasis drug candidate that is in Phase II clinical trial. It also focuses on the development of Brilacidin, an antibiotic candidate for the treatment of acute bacterial skin and skin structure infection, oral mucositis, and inflammatory bowel disease, and ulcerative proctitis/colitis; and defensin-mimetics for otic infections, diabetic foot infections, and hidradenitis suppurativa indications.
TypePublic
HQBeverly, US
Founded2007
Size (employees)15 (est)
Websiteipharminc.com
Innovation Pharmaceuticals was founded in 2007 and is headquartered in Beverly, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Innovation Pharmaceuticals

Leo Ehrlich

Leo Ehrlich

CEO
Arthur Bertolino

Arthur Bertolino

President
Show more

Innovation Pharmaceuticals Office Locations

Innovation Pharmaceuticals has an office in Beverly
Beverly, (HQ)
151 100 Cummings Center
Show all (1)
Report incorrect company information

Innovation Pharmaceuticals Financials and Metrics

Innovation Pharmaceuticals Revenue

USD

Net income (FY, 2018)

(16.4m)

EBIT (FY, 2018)

(13.9m)

Market capitalization (8-Oct-2018)

38.9m

Cash (30-Jun-2018)

2.4m
Innovation Pharmaceuticals's current market capitalization is $38.9 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

General and administrative expense

872.0k1.2m1.9m1.3m1.4m

R&D expense

6.3m10.5m9.0m12.8m11.4m

Operating expense total

8.0m13.0m12.7m15.3m13.9m

EBIT

(8.0m)(13.0m)(12.7m)(15.3m)(13.9m)
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q3, 2018

General and administrative expense

244.0k275.0k339.0k352.0k249.0k362.0k344.0k331.0k295.0k

R&D expense

1.9m2.3m1.8m2.1m3.0m2.3m2.7m3.2m1.8m

Operating expense total

2.2m2.6m2.2m3.3m3.7m3.0m3.3m3.9m2.4m

EBIT

(2.7m)(2.8m)(2.5m)(3.3m)(3.7m)(3.0m)(3.3m)(3.9m)(2.4m)
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

5.0m8.4m6.3m4.1m2.4m

Current Assets

5.6m8.8m6.7m4.5m2.6m

Total Assets

10.9m14.3m11.4m9.1m6.5m

Accounts Payable

42.2m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q3, 2018

Cash

7.1m9.5m10.8m7.8m6.2m5.3m5.6m3.9m5.6m1.3m

Current Assets

7.2m9.6m11.4m8.0m6.4m5.8m6.2m4.1m5.7m1.5m

Total Assets

12.5m14.9m17.1m13.5m11.9m11.3m10.9m8.8m10.5m5.8m

Current Liabilities

8.0m7.7m7.3m7.5m7.6m8.4m8.8m8.7m9.3m9.5m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(8.2m)(13.1m)(12.9m)(15.5m)(16.4m)

Accounts Payable

815.0k(826.0k)1.7m1.2m(1.5m)

Cash From Operating Activities

(7.5m)(13.1m)(9.9m)(11.7m)(13.3m)

Purchases of PP&E

(43.0k)(9.0k)(68.0k)
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

(2.8m)(2.9m)(2.6m)(5.9m)(9.6m)(3.0m)(3.4m)(3.9m)

Accounts Payable

259.0k1.3m

Cash From Operating Activities

(4.6m)(7.7m)

Purchases of PP&E

(68.0k)
USDY, 2018

Financial Leverage

-3 x
Show all financial metrics
Report incorrect company information

Innovation Pharmaceuticals Online and Social Media Presence

Embed Graph
Report incorrect company information

Innovation Pharmaceuticals News and Updates

Innovation Pharmaceuticals Provides Corporate Update Highlighting Business Development and Clinical Pipeline Priorities

BEVERLY, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to provide a corporate update highlighting business development and clinical pipeline priorities across its first-in-class drug candidat…

Innovation Pharmaceuticals Provides Update on Kevetrin Program; Bridging Toxicology Efforts Aimed at Developing an Oral p53 Anti-Cancer Drug Candidate

BEVERLY, Mass., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to provide a development update on the Company’s p53 anti-cancer drug candidate Kevetrin. The Company is in the process of selecting a C…

Innovation Pharmaceuticals Brilacidin as a Novel Inhibitor of Phosphodiesterase 4 (PDE4) Supports its Potential to Treat Autoimmune and Inflammatory Diseases; Company Invited to Present at Upcoming Crohn’s & Colitis Foundation Conference

BEVERLY, Mass., Oct. 12, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to provide this update on Brilacidin as a novel inhibitor of Phosphodiesterase 4 (PDE4), an important aspect of its mechanism of action…

Innovation Pharmaceuticals Secures Up to $10 Million in Additional Financing to Advance Clinical Pipeline

BEVERLY, Mass., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that it has secured new financing for up to $10 million from one multi-family office focused on healthcare and life sciences,…

Innovation Pharmaceuticals Provides a Comparative Perspective on Brilacidin’s Potential to Unlock the Oral Mucositis Market: Pharma Industry Attacks Severe Pain and Suffering Due to Cancer Treatments

BEVERLY, Mass., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to provide a comparative perspective on the development of Brilacidin for the prevention of severe Oral Mucositis (SOM) in Head and Nec…

Innovation Pharmaceuticals to Present Brilacidin for Inflammatory Bowel Disease at Inaugural “IBD Innovate 2018” Conference Hosted by the Crohn’s & Colitis Foundation

BEVERLY, Mass., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today that the Company has been invited to present on the planned continued development of Brilacidin for Inflammatory Bowel Disease at …
Report incorrect company information

Innovation Pharmaceuticals Blogs

Innovation Pharmaceuticals Wishes Shareholders a Happy Thanksgiving

Dear IPIX Shareholders,In just a few short weeks, we will be convening our Brilacidin-Oral Mucositis End-of-Phase 2 regulatory meeting. Success here not only would help us to complete development of the drug, but also to advance other aspects of our clinical pipeline.We appreciate your support and w…

Innovation Pharmaceuticals Presenting Brilacidin for Inflammatory Bowel Disease at “IBD Innovate 2018” Conference Hosted by the Crohn’s & Colitis Foundation

BEVERLY, MA – November 13, 2018 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to announce that the Company is presenting a scientific poster—Brilacidin for Inflammatory Bowel Disease: A Novel, Non-Corticosteroid, Non-…

Innovation Pharmaceuticals Expands Brilacidin Patent Portfolio

BEVERLY, MA – November 1, 2018 (GLOBE NEWSWIRE) Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that the U.S. Patent & Trademark Office recently announced the allowance of another application directed to Brilacidin.The “N…

Innovation Pharmaceuticals Granted End-of-Phase 2 Meeting

BEVERLY, MA – October 24, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted an End-of-Phase 2 meeting with Innovation Pharmaceuticals for its clinical…

Innovation Pharmaceuticals Brilacidin as a Novel Inhibitor of Phosphodiesterase 4 (PDE4) Supports its Potential to Treat Autoimmune and Inflammatory Diseases

Company Invited to Present at Upcoming Crohn’s & Colitis Foundation ConferenceBEVERLY, MA – October 12, 2018 (GLOBE NEWSWIRE) Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to provide this update on Brilacidin as a novel inhibitor…

Brilacidin for Oral Mucositis: At-a-Glance Comparative Data Presentation with Other Investigational OM Drugs

The primary efficacy endpoint evaluated in the Brilacidin Phase 2 clinical trial (see NCT02324335) was incidence of severe Oral Mucositis (SOM) (WHO Grade ≥3). The percentage of incidence reduction (if any) of SOM between the active arm versus placebo group can be expressed as a relative difference.…
Show more

Innovation Pharmaceuticals Company Life and Culture

Report incorrect company information

Innovation Pharmaceuticals Frequently Asked Questions

  • When was Innovation Pharmaceuticals founded?

    Innovation Pharmaceuticals was founded in 2007.

  • Who are Innovation Pharmaceuticals key executives?

    Innovation Pharmaceuticals's key executives are Leo Ehrlich and Arthur Bertolino.

  • How many employees does Innovation Pharmaceuticals have?

    Innovation Pharmaceuticals has 15 employees.

  • Who are Innovation Pharmaceuticals competitors?

    Competitors of Innovation Pharmaceuticals include SciBac, Cellestia Biotech and Alvine Pharmaceuticals.

  • Where is Innovation Pharmaceuticals headquarters?

    Innovation Pharmaceuticals headquarters is located at 151 100 Cummings Center, Beverly.

  • Where are Innovation Pharmaceuticals offices?

    Innovation Pharmaceuticals has an office in Beverly.

  • How many offices does Innovation Pharmaceuticals have?

    Innovation Pharmaceuticals has 1 office.